ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations

Published Date: 03 Jun 2025

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, leads to significantly ...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Authorizes Three Different Uses for Injectable Antibiotic.

2.

Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.

3.

Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.

4.

Distribution of fat could influence cancer risk, study suggests

5.

For the first time in humans, a chemotherapy drug reaches the brain.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot